The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy

• Main Authors: Chih-Jen Yang (Author), Jen-Yu Hung (Author), Ming-Ju Tsai (Author), Kuan-Li Wu (Author), Ta-Chih Liu (Author), Shah-Hwa Chou (Author), Jui-Ying Lee (Author), Jui-Sheng Hsu (Author), Ming-Shyan Huang (Author), Inn-Wen Chong (Author)
• Format: Book
• Published: BMC, 2017-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib can provide better efficacy and prolonged progression free survival (PFS) than cytotoxic chemotherapy for metastatic lung non-squamous cell carcinoma harboring susceptible EGFR mutations whe...